- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Eytan M. Stein, MD | Authors
Articles
Phase I Results for Enasidenib in AML
June 07, 2017
Video
Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant IDH-2 relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.